首页> 外文期刊>Colloids and Surfaces, B. Biointerfaces >Nano scale self-emulsifying oil based carrier system for improved oral bioavailability of camptothecin derivative by P-Glycoprotein modulation
【24h】

Nano scale self-emulsifying oil based carrier system for improved oral bioavailability of camptothecin derivative by P-Glycoprotein modulation

机译:纳米级自乳化油基载体系统,通过调节P-糖蛋白改善喜树碱衍生物的口服生物利用度

获取原文
获取原文并翻译 | 示例
           

摘要

Irinotecan is a camptothecin derivative with low oral bioavailability due to active efflux by intestinal P-glycoprotein receptors. Hence, no oral formulation is marketed for Irinotecan till date. However, an optimized Self micro emulsifying drug delivery system (SMEDDS), formulated to produce nano range oil droplets by using P-gp modulator excipients can tackle the issue and elevate the systemic availability of Irinotecan. The present work focuses on the development of SMEDDS for Irinotecan and evaluation of its in vitro, ex vivo and in vivo potentials. The SMEDDS were developed using Capmul MCM-C8, Cremophor EL and Pluronic L-121 as oil, surfactant and co-surfactant respectively and has good oil carrying capacity (30%) with competence to produce nano-scale oil droplets (130±2.13nm) on spontaneous emulsification. A much deeper penetration to the intestine was observed with SMEDDS by using confocal laser scanning microscopy (CLSM). Flow-cytometric studies also revealed the greater uptake of fluorescent probe in Caco-2 cell-lines with the use of SMEDDS. Biochemical estimation of LDH from the intestinal tissues treated with SMEDDS and free drug suspension confirmed that the developed formulation is safe for use. Furthermore, the AUC_(0→t) of Irinotecan from the optimized SMEDDS formulation was found to be 4 folds higher than that from Irinotecan suspension on oral administration. The optimized SMEDDS formulation was found to be capable of maintaining the sustained plasma drug level of Irinotecan with better bioavailability.
机译:伊立替康是喜树碱衍生物,由于肠道P-糖蛋白受体的主动外排,口服生物利用度低。因此,迄今为止,尚无用于伊立替康的口服制剂上市。但是,经过优化的自微乳化药物输送系统(SMEDDS),通过使用P-gp调节剂赋形剂可产生纳米范围的油滴,可以解决此问题并提高伊立替康的全身利用率。目前的工作集中在开发用于伊立替康的SMEDDS并评估其体外,离体和体内潜能。 SMEDDS是使用Capmul MCM-C8,Cremophor EL和Pluronic L-121分别作为油,表面活性剂和助表面活性剂开发的,具有良好的载油能力(30%),具有产生纳米级油滴(130±2.13nm)的能力。 )自发乳化。通过使用共聚焦激光扫描显微镜(CLSM),使用SMEDDS观察到了更深的肠渗透。流式细胞术研究还表明,使用SMEDDS可以使Caco-2细胞系中的荧光探针吸收更多。用SMEDDS和游离药物悬浮液处理过的肠道组织中LDH的生化估计证实了所开发的制剂可安全使用。此外,发现来自优化的SMEDDS制剂的伊立替康的AUC_(0→t)比口服给药时的伊立替康悬浮液的AUC_(0→t)高4倍。发现优化的SMEDDS制剂能够以更好的生物利用度维持伊立替康的持续血浆药物水平。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号